Form S-8 BioAge Labs, Inc.
BioAge Labs, Inc. (BIOA)
Last bioage labs, inc. earnings: 8/3 07:00 am
Check Earnings Report
US:NYSE Investor Relations:
investor.bio-amber.com
Company Research
Source: SEC EDGAR
Impact Snapshot
Event Time:
BIOA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BIOA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BIOA alerts
High impacting BioAge Labs, Inc. news events
Weekly update
A roundup of the hottest topics
BIOA
News
- BioAge Labs Reports Full Year 2025 Financial Results and Provides Business Updates from the Fourth Quarter of 2025GlobeNewswire
- New data on long-term, real-world treatment with lecanemab presented at the 2026 AD/PD™ congressPR Newswire
- BioAge Labs (BIOA) had its price target raised by Citigroup Inc. from $15.00 to $52.00. They now have a "buy" rating on the stock.MarketBeat
- BioAge Labs Touts Oral NLRP3 Inhibitor BGE-102 Data, Eyes CV Study and Retinal Expansion [Yahoo! Finance]Yahoo! Finance
- BioAge Labs (BIOA) is now covered by Oppenheimer Holdings, Inc.. They set an "outperform" rating and a $60.00 price target on the stock.MarketBeat
BIOA
Earnings
- 3/24/26 - Miss
BIOA
Sec Filings
- 3/24/26 - Form S-3ASR
- 3/24/26 - Form 10-K
- 3/24/26 - Form 8-K
- BIOA's page on the SEC website